Company profile

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPHBiotechnology: Pharmaceutical Preparations

Drug pipeline (15)

AssetStageRevenueTrialsStatus
Bupivacaine Hydrochlorideapproved0
COSYNTROPINapproved0
ENOXAPARIN SODIUMapproved6approved
GANIRELIX ACETATEapproved0
Glucagonapproved7approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (20)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00634517phase3terminated2008-03-012008-12-01Amphastar Pharmaceuticals, Inc.4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
NCT01581177phase2completed2012-04-012012-07-01Amphastar Pharmaceuticals, Inc.Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation
NCT02210806phase2completed2014-07-012014-09-01Amphastar Pharmaceuticals, Inc.Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
NCT01737892phase1_2terminated2012-11-012012-11-01Amphastar Pharmaceuticals, Inc.Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
NCT05539872phase2_3completed2022-08-222023-01-29Amphastar Pharmaceuticals, Inc.Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

FDA applications (18)

ApplicationTypeApplicantProducts
ANDA 076209ANDAAMPHASTAR PHARMACEUTICAL INC
ANDA 076684ANDAAMPHASTAR PHARMACEUTICAL INC
ANDA 077235ANDAAMPHASTAR PHARMACEUTICALS INC
ANDA 077334ANDAAMPHASTAR PHARMACEUTICALS INC
ANDA 208086ANDAAMPHASTAR PHARMACEUTICALS INC